ArticleBiological psychiatry2026
Targeting Mu Opioid Receptor Neurons of the Habenula to Limit Naloxone Aversion.
Article in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundOpioid use disorder is a chronic relapsing condition that continues to rise worldwide. Naloxone, an opioid antagonist, reverses overdose but triggers strong negative affect. The neuronal circuits underlying these aversive effects remain unclear. We previously identified mu opioid receptor-expressing habenular neurons (Hb-MOR) as key encoders of negative emotional states and hypothesized that they also mediate naloxone aversion.
methodsWe combined behavioral models of naloxone aversion with in vivo fiber photometry to monitor Hb-MOR activity in opioid-naïve and -dependent mice. Causality was tested through chemogenetic silencing of Hb-MOR neurons. Finally, we targeted GPR139, an anti-opioid orphan receptor enriched in the habenula, to pharmacologically modulate naloxone responses.
resultsIn opioid-naïve mice, high-dose naloxone induced conditioned place aversion (CPA) and increased Hb-MOR neuron activity, both of which were prevented by chemogenetic inhibition. In dependent animals, low-dose naloxone was sufficient to activate Hb-MOR neurons and produce CPA. Silencing Hb-MOR neurons abolished these effects and alleviated somatic withdrawal signs, indicating enhanced sensitivity of these neurons in dependence. Targeting GPR139 provided a therapeutic approach: The GPR139 antagonist JD-1 reduced Hb-MOR responses to naloxone and attenuated both somatic and affective withdrawal symptoms in morphine-dependent mice.
conclusionsHb-MOR neurons are key to naloxone-induced aversion and withdrawal. Pharmacological modulation of GPR139 represents a promising strategy to limit adverse effects associated with naloxone and opioid withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.